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Background: There are still several controversies and ambiguities in the aspects of primary hepatic squamous cell
carcinoma and primary hepatic adenosquamous carcinoma. To further clarify the specific features of these two
infrequent diseases and provide beneficial propose for clinical decision, we did this retrospective study.
Methods: We reviewed the clinical features and outcomes of three primary hepatic squamous cell carcinoma (SCC)
patients and six primary hepatic adenosquamous carcinoma (ASC) patients from January 1998 to December 2011 in
Eastern Hepatobiliary Surgery Hospital in China. Meanwhile, 40 hepatocellular carcinoma (HCC) patients and 26
metastatic hepatic SCC or ASC patients who were hospitalized in the same period were also reviewed to make a
comparison. In order to find out the definite survival information of SCC and ASC patients, 30 previous studies
containing 37 primary hepatic SCC (16) and ASC (21) patients were reviewed, and their information of survival was
analyzed together with the included patients in our hospital.
Results: Serum tumor markers showed significant differences between primary hepatic SCC/ASC and HCC patients,
especially for serum alpha fetal protein (AFP) level and carbohydrate antigen 19-9 (CA 19-9). On the pathologic
performance, primary SCC/ASC tumor was rarely accompanied with tumor capsule. They presented peripheral
hepatic lymph node metastasis more likely and showed low proportion of microvascular invasion. The median
survival time of primary hepatic SCC/ASC patients after liver resection (LR) was 15 months. And the 1-, 3-, 5-year
survival rates after LR were 60%, 24%, and 12%, respectively. Significant difference was not discovered when SCC
and ASC patients were compared with HCC patients (P = 0.294). The median survival time after LR for primary SCC
and ASC patients was respectively 23 months and 13 months.
Conclusions: The comprehensive application of some clinical characteristics, histopathologic features, and imaging
findings may be useful for us in making definite diagnoses for primary hepatic SCC and ASC patients
preoperatively. And the treatment of liver resection was effective for those patients who met the selection criteria
for liver resection.
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Due to the prevalence of hepatitis and some other reasons,
the morbidity of primary liver tumor is high in Asia, espe-
cially in China [1]. Though the majority of the primary tu-
mors are hepatocellular carcinoma (HCC), some rare
diseases also could not be ignored by the reason of their
characteristics. Both primary hepatic squamous cell car-
cinoma (SCC) and adenosquamous carcinoma (ASC) are
very rare. Few of them have been reported in the litera-
tures. Primary hepatic SCC was considered to be associ-
ated with hepatic cysts [2-5], hepatolithiasis [6,7] Caroli’s
disease [8], and others. Primary hepatic ASC was defined
as a liver tumor containing definite components of both
adenocarcinoma and squamous cell carcinoma, and some-
times it was considered as a variant of cholangiocarcinoma
[9]. However, it was observed to have more aggressive
clinical and pathological features than cholangiocarcinoma
[10]. Both of SCC and ASC have squamous cell carcinoma
components. These tumor components presented more
malignant biological behavior, and that may be the com-
mon reason for the poor prognosis of the both [11].
We retrospectively investigated some primary hepatic
SCC or ASC patients in our hospital to research the
characteristics of these two kinds of diseases. Meanwhile,
some patients in previous studies were also reviewed.
Methods
Patients
A total of 75 liver tumor patients, who had received liver
resection (LR) during the period from January 1998 to
December 2011 in Eastern Hepatobiliary Surgery Hospital,
were picked out and included in this study.
There were just nine patients who suffered from histo-
logically proven primary hepatic SCC (three patients) or
ASC (six patients) had surgical treatment during the
14 years in our hospital, and all of them were included
as the primary SCC/ASC group. Before their final diag-
noses were made, each of these nine primary tumor pa-
tients had undergone imageological examination and
hematological and blood biochemical determinations to
preclude other primary tumor diseases. The HCC group
contained 40 patients who were selected randomly from
our data base. Considering the significant impact of liver
cirrhosis to the prognosis of liver cancer patients and
half of patients in the primary SCC/ASC group had liver
cirrhosis (four patients), the HCC group patients were
picked randomly according to the factor that nearly half of
patients suffered cirrhosis and half did not. Twenty-six pa-
tients with metastatic hepatic SCC (16 patients) or ASC
(10 patients) in the hospital during the same time com-
posed the metastatic SCC/ASC group. The primary car-
cinomas of these patients contained lung cancer (12
patients, 46.2%), nasopharynx cancer (5 patients, 19.2%),
gallbladder carcinoma (5 patients, 19.2%), esophaguscancer (3 patients, 11.5%), and vocal cord carcinoma (1
patients, 3.8%).
We only compared the metastatic SCC/ASC patients
with the primary SCC/ASC patients on histopathologic
findings. That was because in the clinical practice, it is
difficult to determine whether the tumor is primary or
metastatic by the postoperative histopathologic examin-
ation if other primary sites have not been discovered. So
we intended to find some differences between them. All of
the other comparisons, like demographic data, operative
and laboratory findings, survival, were carried out between
the primary SCC/ASC group and the HCC group.Clinical and laboratory data
The clinical and laboratory data of the primary SCC/
ASC patients and HCC patients were reviewed retrospect-
ively from the medical records and relevant databases of
Eastern Hepatobiliary Surgery Hospital in China.
To analyze the clinical data, we reviewed the operation
notes, like the number and size of tumors, TNM stage,
and capsule of the tumors. The laboratory examinations
were performed preoperatively, and the laboratory data
contained biochemical tests, which reflected hepatic
damage, such as prothrombin time (PT), total bilirubin
(TBIL), serum alanine transaminase (ALT), and aspartate
transaminase (AST). The data of serum alpha fetal pro-
tein (AFP), serum carbohydrate antigen 19-9 (CA 19-9),
and serum carcinoembryonic antigen (CEA) before LR
was analyzed at the same time. We also summarized the
features of patients’ imagining and pathologic findings.Survival data
We retrospectively referred to the record databases and
completed the follow-up work to get the data associated
with survival. Forty-nine patients in the primary SCC/
ASC group and the HCC group were followed up regu-
larly until death or until the completion time of the data
collecting work and writing the manuscript. The follow-
up visit was conducted by phone.
As there were just nine primary hepatic SCC/ASC pa-
tients included in our study, in order to reduce the bias
which might be brought by small sample, we reviewed
some previous studies, and then synthetically analyzed
the survival data they contained. We collected English
papers and a few Chinese papers, which should have
English abstracts, from Medline and Pubmed. The in-
cluded studies should have the exact information of pa-
tients’ prognosis. All of the included patients should
have no other tumor diseases and have accepted hepatic
resections when their initial diagnosis had been made,
and patients who died during the operation or few days
after the operation would be excluded. Finally, 30 previ-
ous studies containing 37 primary hepatic SCC (16) and
Table 1 The demographic data and baseline characteristics
of primary hepatic SCC/ASC patients and HCC patents
Primary SCC/ASC
group
HCC group χ2/F/t P
Patients 9 40 - -
Gender
Male 7(77.8%) 33(82.5%) 0.105 0.746
Female 2(22.2%) 7(17.5%)
Age (years) 57.89 ± 11.062 54.55 ± 11.701 0.781 0.439
Cirrhosis
Yes 4(44.4%) 21(52.5%) 0.005 0.946
No 5(55.6%) 19(47.5%)
AFP
≤10 ng/ml 8(88.9%) 14(35%) 6.583 0.010
>10 ng/ml 1(11.1%) 26(65%)
CA 19-9
≤37 U/ml 4(44.4%) 39(97.5%) 14.625 0.000
>37 U/ml 5(55.6%) 1(2.5%)
Prothrombin
time (second)
12.24 ± 1.098 12.11 ± 1.153 0.288 0.775
TBIL
≤2 mg/dl 8(88.9%) 27(67.5%) 0.766 0.382
>2 mg/dl 1(11.1%) 13(32.5%)
ALT
≤40 U/l 6(66.7%) 17(42.5%) 0.889 0.346
>40 U/l 3(33.3%) 23(57.5%)
AST
≤34 U/l 6(66.7%) 20(50%) 0.287 0.592
>34 U/l 3(33.3%) 20(50%)
Extent of resection
<Hemihep 7(77.8%) 35(87.5%) 0.051 0.821
≧Hemihep 2(22.2%) 5(12.5%)
Transfusion
Yes 7(77.8%) 23(57.5%) 0.562 0.454
No 2(22.2%) 17(42.5%)
Postoperative TACE
Yes 3(33.3%) 24(60%) 1.171 0.279
No 6(66.7%) 16(40%)
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the survival information [12-33].
Statistical analysis
The analyses were carried out by using SPSS 20. All data
were presented as a median or the mean ± standard devi-
ation (SD). The independent two-sample t-test was used
to compare the numerical data. The Pearson chi-square
test and Fisher’s exact test were performed for qualitative
data. And the One-way analysis of variance (ANOVA),
Kaplan-Meier, Cox regression analysis, was also used. A P
value at <0.05 was regarded as statistically significant.
The study was approved by the Ethics Committee
Eastern Hepatobiliary Surgery Hospital (approved num-
ber: EHBHKY-005-7), informed consent which has been
conducted according to the principles expressedin the
Declaration of Helsinki was obtained from each patient.
All participantsprovided their written informed consent
to participate in this study
Results
Demographic data and baseline characteristics
All related information of the primary SCC/ASC pa-
tients (9 patients) and primary HCC patients (40 pa-
tients) were summarized in Table 1 for the comparison
of the demographic data and clinical characteristics.
These two groups of patients shared almost the same
gender and age composition. Of these patients, 7
(77.8%) men and 2 (22.2%) women were in the primary
SCC/ASC group, and 33 (82.5%) men and 7 (17.5%)
women were in the HCC group (P = 0.746). The average
age was respectively 57.89 ± 11.062 and 54.55 ± 11.701
(P = 0.439). To maintain consistent baselines for all pa-
tients, the HCC group patients were selected according
to the component ratio of patients with or without cir-
rhosis in the primary SCC/ASC group. So there were
also no significant differences between these two groups
of patients on the baseline liver function indexes, like
TBIL, ALT, AST, and PT.
Serum tumor markers showed significant differences
for these two groups patients due to the different tumor
tissues. As a classical marker of HCC, serum AFP level
appeared to have higher frequency of exceeding normal
value in HCC patients (P = 0.01) and there was only one
primary ASC patient (no primary SCC patient) who was
detected with a high level of serum AFP. However, the
performance of CA 19-9 was just the opposite. When
we defined 37 U/ml was the highest normal level of
serum CA 19-9, we found only one (2.5%) HCC patient
exceeded this standard value, and the ratio was much
less than primary SCC/ASC patients (P = 0.000).
Three (33.3%) patients in primary SCC/ASC group and
24 (60%) patients in HCC group adopted postoperative
transhepatic arterial chemotherapy and embolization.
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tumor size was chosen when several tumors were found in
a patient), we found the average diameter of the tumors
was generally large (>5 cm) for both two groups of pa-
tients (P = 0.387). When the primary liver tumors were
staged by the TNM stage system [12], the primary SCC/
ASC patients mainly distributed in stage II or IV, and the
primary HCC patients mainly were stage IV. The extent of
liver resection for most patients were less than hemihepa-
tectomy (77.8% and 87.5%).
Histopathologic findings
The comparison of general pathologic characteristics be-
tween primary SCC/ASC patients and HCC patients was
listed in Table 2. From the result of statistical analysis,
we found that, because the main component was squa-
mous carcinoma, the liver tumor in primary SCC/ASC
patients usually did not accompany tumor capsule. This
feature could make the primary hepatic SCC/ASC show
more malignant biological behavior. Though the differ-
ence was not significant (P = 0.191, >0.05), primary SCC/
ASC patients presented peripheral hepatic lymph node
metastasis more likely (4 patients, 44.4%). This perform-
ance might be related with these liver tumors’ malignant
behavior. The microvascular invasion of tumors was
quite different when comparing the pathology of the two
groups of patients. The microvascular invasion only
emerged in a few part of primary SCC/ASC (2 patients,Table 2 The general pathologic characteristics of primary
SCC/ASC patients and HCC patents
Primary SCC/ASC
group
HCC group χ2/F/t P
Patients 9 40 - -
Tumor capsule
Yes 0 30(75%) 14.392 0.000
No 9(100%) 10(25%)
Macrovascular invasion
Yes 0 3(7.5%) 0.006 0.937
No 9(100%) 37(92.5%)
Microvascular invasion











III 3(33.3%) 30(75%)22.2%) but almost in all of the HCC patients (40 pa-
tients, 100%). The tumor tissues were staged in
Edmondson-Steiner grading [13]. All these liver tumor
patients were mainly distribute in stages II (moderately
differentiated) and III (poorly differentiated). More than
half of the primary SCC/ASC patients (6 patients,
66.7%) were stage II, and 75% of HCC patients (30 pa-
tients) were stage III. It seemed that tumor tissues in
primary hepatic SCC and ASC were better differentiated
than that in HCC.
Microscopically, the postoperative tumor tissue slice of
primary hepatic SCC presented that the cancer cells were
polygonal and arranged as strips, and their nucleuses were
round or orbicular-ovate, most of which even had patho-
logic change, like karyomegaly and anachromasis. No cap-
sule was found around the tumor and it appeared
multifocal growth. Apart from the performance of squa-
mous cancer cells, the tumor tissue of primary hepatic ASC
arranged like glandular tube, adenocarcinoma cells were
cubic or columnar and the tumor appeared infiltrative
growth. We chose two typical HE tumor tissue slices from
the nine primary carcinoma patients (Figure 1), of whom
one was primary SCC (A), and the other was ASC (B).
In order to find the immunohistochemical characteris-
tics of hepatic tumor pathology for primary SCC and
ASC, we compared some immunohistochemical markers
of tumor tissues between primary hepatic SCC/ASC and
metastatic hepatic SCC/ASC (Table 3). Unlike the meta-
static tumor group (80% positive CK 19), all of the primary
group patients expressed positive CK 19, and a half of the
primary hepatic ASC patients (three patients) even had
strong positive expression. Considering that CK 19 gener-
ally appeared positive in the cholangiocellular carcinomas
[34], the different performance of CK 19 between the four
groups may provide some revelations for the origin of pri-
mary hepatic SCC and ASC. We found the percentage of
positive CK 18 for primary SCC patients was larger than
that of metastatic SCC (valid percent, 66.7%:42.9%), and
that was also adapted to the comparison between primary
ASC and metastatic ASC (valid percent, 83.3%:75%).
Two patients in primary hepatic SCC group (1 did not
have the test) were negative for CEA, and in contrast to that,
all primary hepatic ASC patients (5 patients) were positive
for CEA, excepted 1 person who did not conduct the test.
Survival
As mentioned above, because the survival of the meta-
static hepatic SCC and ASC patients might be signifi-
cantly affected by the primary tumor disease, it was
insufficient to analyze the survival just basing on the
metastatic hepatic tumor diseases. So the survival ana-
lysis was only conducted in primary SCC/ASC and HCC
patients (total 49 patients). The median time of follow-
up was 20 months, arranged from 4 to 72 months. Till
Figure 1 Two typical HE tumor tissue slices. (A) The squamous cancer cells were polygonal and arranged as strips, and their nucleuses were
round or orbicular-ovate, most of which even had pathologic change, like karyomegaly and anachromasis (H & E stain, ×200). (B) Except the performance
of squamous cell carcinoma components, adenocarcinoma cells were cubic or columnar and arranged like glandular tube (H & E stain, ×200).
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alive in the primary SCC/ASC group. The median time
of survival for these nine patients after LR was
15 months, and the mean of survival time was 19.778 ±
4.389 months. Primary SCC/ASC patients’ 1-, 3-, 5-year
survival rates after LR were 67%, 20%, and 0%. For the
40 included HCC patients in this study, the median sur-
vival time after LR was 23 months and the mean of sur-
vival time was 29.405 ± 3.614 months. We also found
their 1-, 3-, 5-year survival rates after LR were 68%, 35%,
and 14%. The short-term survival after LR of these two
groups of patients was nearly the same, but the long-
term survival of the HCC patients seemed better than
that of the primary SCC/ASC patients. However, we
found no significant difference of the overall survivalTable 3 The immunohistochemical characteristics of









Patients 3 6 16 10
CK 18
Negative 1(33.3%) 1(16.7%) 8(57.1%) 2(25%)
Positive 2(66.7%) 5(83.3%) 6(42.9%) 6(75%)
CK 19
Negative 0 0 3(20%) 2(20%)
Positive 3(100%) 6(100%) 12(80%) 8(80%)
CEA
Negative 2(100%) 0 4(36.4%) 0
Positive 0 5(100%) 7(63.6%) 10(100%)between two groups of patients (log rank χ2 = 1.216, P =
0.27, Figure 2).
From the review of 30 previous studies, we extracted
the survival information of 37 primary SCC (16, 43.2%)
and ASC (21, 56.8%) patients, and their survival data
was mixed together with our patients’ data to conduct
the survival analysis. All of the 37 primary SCC/ASC
patients from previous studies and our 9 primary SCC/
ASC patients were defined as total primary SCC/ASC
group (46 patients), which would be compared with
those 40 HCC patients. The median survival time after
LR of the total primary SCC/ASC patients was
15 months, which was the same with our included 9
SCC/ASC patients in our hospital. And the mean sur-
vival time after LR was 26.187 ± 4.876 months. The 1-,
3-, 5-year survival rates after LR for these primary SCC/
ASC patients were 60%, 24%, 12%, respectively. We also
did not find any significant difference when compared
with HCC patients (log rank χ2 = 1.100, P = 0.294,
Figure 3). At the same time, we compared all of primary
SCC patients (19 patients) and primary ASC patients
(27 patients) with HCC patients (40 patients), respect-
ively. The median survival time after LR for primary
SCC and ASC patients was 23 and 13 months. The 1-, 3-,
5-year survival rates after LR were 72%, 27%, and 18% and
51%, 21%, and 7% for SCC patients and ASC patients.
Though the survival rates appeared to be different, from
the analysis of comparison result, no significant difference
was found when we compared the SCC and ASC patients
with HCC patients respectively (log rank χ2 = 4.330, P =
0.115, Figure 4). This result was similar with what we ob-
tained from the comparison of patients in our hospital. So
from the statistical analysis results, we found that the
Figure 2 Kaplan-Meier cumulative survival curves of the two
groups of patients for overall survival (OS). Figure 4 Kaplan-Meier cumulative survival curves of primary
SCC, ASC, and HCC group of patients for overall survival (OS)
after liver resection.
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tients seemed similar with HCC patients.
Discussion
Though various hypotheses have been set forth previ-
ously, the pathogenesis and precise steps leading up to
the development of the carcinomas for both primary
hepatic SCC and ASC are not exactly clear. Previous
studies had reported that potentially pre-existent dis-
eases, like hepatic cysts, containing congenital hepatic
cyst or other benign non-parasitic cysts [2-5], calculus of
intrahepatic duct [6], Caroli’s disease [7,8], may be theFigure 3 Kaplan-Meier cumulative survival curves of the total
primary SCC/ASC group (added 37 patients from previous
studies) and HCC group of patients for overall survival (OS)
after liver resection.aetiological agents for primary hepatic SCC. In our pri-
mary SCC patients group, one patient had liver cirrhosis,
and two had hepatic cyst, which was in accord with pre-
vious reports and might explain the pathogenesis. Simi-
larly, though some pathogenesis of primary hepatic ASC
had been proposed previously, it was still undefined. It
was suggested in some previous studies that primary hep-
atic ASC might be caused by the squamous metaplasia of
the intrahepatic bile duct [31]. The pathogenesis was
also believed to be that the chronic inflammation con-
tinuously irritated the bile ducts or various congenital
cysts of the biliary tracts [32], while someone proposed
squamous metaplasia of denocarcinoma cells might be
the etiologic factors [35]. In our study, the six included
primary ASC patients contained one liver cirrhosis pa-
tients, one calculus of intrahepatic duct patients, and
three hepatic cyst patients, which was also complied
with those previous opinions about the pathogenesis of
primary hepatic ASC.
Since the absence of sufficient evidence and undeter-
mined pathogenesis for both primary hepatic SCC and
ASC, most patients’ preoperative diagnosis could not be
confirmed timely. A previous study reported that the level
of serum squamous cell carcinoma-related antigen (SCC-
Ag) might be a useful marker for preoperative diagnosis
for ASC [36]. They found patients suffering from primary
hepatic ASC might have a high level of serum SCC-Ag
and this marker could also indicate tumor recurrence. In
this paper, none of our primary hepatic SCC or ASC pa-
tients had definitive preoperative diagnosis.
We summarized and analyzed some kinds of preopera-
tive clinical data and compared them between primary
hepatic tumor (SCC and ASC) and HCC groups to
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with primary hepatic SCC and ASC shared the similar
performance of common serum tumor biomarkers, like
negative level of AFP (≤10 ng/ml), and a part of positive
level of CA 19-9 (>37 U/ml) that may distinguish them
from most hepatocellular carcinoma and part of meta-
static liver tumor, but it was incapable of picking them
out from other kinds of metastatic liver tumor and most
of usual intrahepatic cholangiocarcinoma. The imaging
performance of primary hepatic SCC and ASC in our
study did not have much unique characteristic. The CT
images could tell a low density mass with irregular rim
enhancement for primary hepatic SCC and ASC, which
was similar to the presentations of intrahepatic cholan-
giocarcinoma, metastatic liver tumor, or even liver ab-
scess. The imaging findings of primary SCC and ASC
patients in our study were almost the same with previ-
ous reports, and they also found most of the MRI of pri-
mary hepatic SCC and ASC presented a low signal on
T1WI image and high signal on T2WI image [33].
Someone detected that the ASC had a performance of
high-signal T1WI image, which might relate to its solid-
cystic structure and central necrosis [30,37].
Though a feasible and determinate preoperative diag-
nostic approach has not been established yet for primary
hepatic SCC and ASC patients, the comprehensive appli-
cation of testing tumor biomarkers, like AFP, CA19-9,
and especially SCC-Ag, could be useful. At present, the
definitive diagnosis is made on the basis of preoperative
needle biopsy, or even has to rely on postoperative histo-
logical and immunohistochemical findings.
At present, both of the therapeutic regimes for pri-
mary hepatic SCC and ASC are not certain, due to the
low incidence and belated definitive diagnosis. Surgical
procedures may be a more important treatment for both
two [6-11,25-33]. Besides the resection, previously re-
ported methods included transcatheter arterial infusion
chemotherapy (TACE), which was considered to be use-
ful for both primary hepatic SCC and ASC patients [22].
Systemic chemotherapy was also reported in the thera-
peutic course of SCC and ASC [21,33]. Although these
therapeutic methods were reported to have significant
treatment effects, they usually were adopted just as adju-
vant therapy [29]. In previous studies, whether TACE or
systemic chemotherapy was always undertaken before or
post resections.
With the high malignancy of tumor, most of the pri-
mary SCC and ASC patients had dismal prognosis [38].
The squamous cell carcinoma components always present
more malignant biological behavior, and it may be the
common reason for the poor prognosis of these two dis-
eases [39]. Takahashi found that, even in primary adenos-
quamous carcinoma of liver, the squamous cell carcinoma
components had highly proliferative activity [9]. But ifsurgery resection was undertaken, the situation might be
improved. From the analysis of the survival data of the in-
cluded patients in our hospital and the patients in the pre-
vious studies, we even did not find any significant
difference between the primary SCC/ASC patients and the
HCC patients about the survival after the treatment of LR
(log rank, P > 0.05). Of course, maybe we can not be so
optimistic because we could not ignore some reasons
which may play roles in achieving this improvement. Be-
cause of the high malignancy of primary hepatic SCC and
ASC, the tumor progresses rapidly, and it certainly leads
to a small number of patients could get the treatment of
LR according to the guideline. The prognoses of the rest
were gloomy and we could not get sufficient information
of this crowd who did not receive surgical treatment yet.
Conclusions
Though it was difficult to make a definite diagnosis for
primary hepatic SCC and ASC patients preoperatively in
the condition that biopsy has not been conducted, there
still were some features for them in clinical characteris-
tics, histopathologic features, and imaging findings. And
the treatment of liver resection was effective for some of
these patients. The low incidence of primary hepatic
SCC and ASC resulted in difficulties to carry out large
sample studies. Multicenter studies could be performed
to further clarify the specific features and to confirm
therapeutic methods.
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